Emma Walmsley signs off in style with stellar GSK results
Shares in UK pharma major GSK (LSE: GSK) were 6% higher late Wednesday after the London-based drugmaker presented its third quarter financial results and updated 2025 guidance.
Sales rose 7% to £8.55 billion ($11.3 billion), some 4% ahead of UBS forecasts, while operating profit was more than 100% higher, at £2.59 billion, 11% above UBS estimates.
GSK upgraded its guidance for 2025 as a whole. Sales growth of between 6% to 7% is now expected, where previously towards the top end of the range of between 3% to 5% was anticipated. Core operating profit growth of between 9% to 11% is now predicted. Previously, the expectation was for towards the top end of the range of between 6% to 8%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze